People
Although the data is not there, Pfizer’s chief executive officer, Albert Bourla, recently said he thought people will “likely” need a booster dose of a vaccine within 12 months of getting fully vaccinated. It’s possible, he also said, they will need to be vaccinated annually.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Amarin announced the forthcoming retirement of President and CEO John Thero, and the elevation of current head of commercial for Europe and senior vice president Karim Mikhail to the top role.
BioSpace takes a look at the annual compensation for the chief executive officers of vaccine developers.
She succeeds Mission Bio’s current chief executive officer Charlie Silver, who will shift into an advisory role with the company he co-founded.
Davidson is one of three new executives to join Cambridge, Mass.-based Tessera.
The biopharmaceutical industry saw two CEO appointments made today, including Howard J. Federoff, M.D., Ph.D., to Brooklyn ImmunoTherapeutics and Eric Koo to Overland ADCT BioPharma.
Gilead CEO Daniel O’Day navigated the company through the turbulent waters of COVID-19 last year, pushing out the very first approved treatment for treatment of the virus. His reward? A $19 million take home.
He’ll make a return to his former role at SV Health Investors as a Venture Partner.
If you’re one of the 17% of Americans that have been fully vaccinated against SARS-CoV-2, you are probably feeling some level of relief. But the CDC warns not to throw your mask away just yet.
PRESS RELEASES